Findings

What do systematic reviews say?

185 questions · 194 findings · 16 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 40 · 20.6%GRADE not reported 15 · 7.7%Very low 29 · 14.9%Low 71 · 36.6%Moderate 35 · 18%High 4 · 2.1%

Targeted immunotherapy alone vs standard targeted therapies

Quality of life: improved to an important degree · previously treated patients with mRCC

Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).

2 findings from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.51 [1.28, 1.78]
1 study · 704 participants
Moderate
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.37
1 study · 703 participants
Moderate

Targeted immunotherapy alone vs standard targeted therapies

Adverse events (grade ≥ 3) · previously treated patients with mRCC

Targeted immunotherapy alone probably leads to lower adverse events (grade ≥ 3) compared with standard targeted therapies (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 0.51 [0.4, 0.65]
1 study · 803 participants
Moderate

Interferon‐α alone vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.17 [1.03, 1.32]
1 study · 408 participants
Low

Interferon‐α combined with targeted therapies vs standard targeted therapies

1‐year mortality · previously untreated patients with mRCC

Interferon‐α combined with targeted therapies showed no clear difference in 1‐year mortality compared with standard targeted therapy (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.13 [0.95, 1.34]
1 study · 419 participants
Moderate

Interferon‐α combined with targeted therapies vs standard targeted therapies

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found